CVS should discuss its expansion plans for HealthHub at a June investor date, and while the stock has tumbled on stalled earnings growth and concerns that margins as a drug-price negotiator will fall, CVS’ assets leave it “uniquely well positioned” for a future when consumers gain more control over healthcare and prices fall, Jack Hough writes in this week’s edition of Barron’s. It might be time to buy the shares, Hough contends.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.